The government's initiatives for social structural reform and healthcare cost reduction have significantly impacted healthcare-related businesses, including pharmaceuticals. The revision of promotion codes and other regulatory changes compel pharmaceutical companies to move away from traditional business practices. However, the vision for what these companies should transform into remains unclear.

Various strategies are being pursued by companies. Some are developing new services and channels using digital technologies, others are strengthening approaches to new players like local governments and care facilities, and some are reimagining the roles of medical representatives (MRs) from scratch while focusing on MR-led promotions. Our firm assists client companies in outlining a direction for reform based on their unique environments, business structures, strengths, organizational cultures, and changes in the external environment, incorporating advanced examples of digital technologies. We support them in implementing these reforms on the ground.

• Formulation of strategies for utilizing data and digital technologies
• Development and validation of new treatment methods, such as digital therapeutics
• Planning and implementation of sales reforms tailored to the company's needs

• Clarification of the Ideal MR Role and Development of Role Models in the Era of Community-based Integrated Care (Domestic Pharmaceutical)
• Support for Planning and Validation of Digital Therapeutics for Specific Diseases (Domestic Pharmaceutical)
• Optimization of Customer Touchpoints in the Digital Era (Foreign Pharmaceutical)
• Examination of Internal Information Infrastructure to Support MRs (Foreign Pharmaceutical)
• Design of Screening Models for Potential Patients of Specific Diseases (Foreign Pharmaceutical)
• Clarification and Establishment of Successful "Public-Private Partnership" Models (Foreign Pharmaceutical)